Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer.

Related Articles

Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer.

Future Oncol. 2018 May 11;:

Authors: Guo D, Zhang J, Jing W, Liu J, Zhu H, Fu L, Li M, Kong L, Yue J, Yu J

Abstract
AIM: We aimed to investigate the association between systemic immune-inflammation index (SII) and the clinical outcomes in patients with advanced non-small-cell lung cancer.
MATERIALS & METHODS: The SII was calculated as platelet (P) × neutrophil (N)/lymphocyte (L), and the data were obtained within 1 week before treatment. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.
RESULTS: Kaplan-Meier analyses revealed that the higher SII group was associated with poorer progression-free survival (p < 0.001) and poorer overall survival (p < 0.001). Multivariable Cox analysis further revealed SII as an independent prognostic factor for overall survival (p = 0.010) and progression-free survival (p = 0.001).
CONCLUSION: SII can serve as a useful biomarker to predict recurrence and death for patients with advanced non-small-cell lung cancer.

PMID: 29747545 [PubMed - as supplied by publisher]

https://ift.tt/2IfNh7l